Leerink Partners Assumes Trevi Therapeutics (TRVI) at Outperform 'based on the potential of lead asset Haduvio'
Tweet Send to a Friend
(Updated - September 9, 2024 12:10 PM EDT)
Leerink Partners analyst Faisal A. Khurshid assumes coverage on Trevi Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Leerink Partners analyst Faisal A. Khurshid assumes coverage on Trevi Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
